Post-Quantum Healthcare Data: A Critical ML-KEM Migration Guide

• A new reference architecture (arXiv:2606.09412v1) wires NIST’s ML-KEM-768 and ML-DSA-65 directly into a working pharmacovigilance data pipeline spanning six components — hospital, gateway, pharma receiver, attacker, benchmarking, and dashboard.
• Benchmarks show ML-KEM key establishment adds only a small constant overhead, while AES-256-GCM encryption and ML-DSA-65 signing dominate runtime as file size grows — meaning your scaling bottleneck is signing, not key exchange.
• For any organization holding adverse-event, clinical-trial, or patient records that must stay confidential for 10+ years, this is the migration template to study before RSA and ECC become a liability.

Why Clinical Data Is Already Living on Borrowed Time

A pharmacovigilance database recording adverse drug reactions does not age out in a quarter. Regulatory retention rules force pharma companies and hospitals to keep that data for decades. That retention window is exactly what makes healthcare the highest-value target for harvest-now-decrypt-later attacks: an adversary copies your TLS-protected exports today, stores the ciphertext, and waits for a cryptographically relevant quantum computer to retroactively break the RSA or elliptic-curve key that protected it.

The researchers behind arXiv:2606.09412v1 frame the threat in plain terms:

“As quantum computing advances, classical public-key cryptographic systems such as RSA and elliptic-curve cryptography may become vulnerable, creating long-term risks for healthcare data that must remain confidential for many years.” — Towards Post-Quantum Secure Pharmacovigilance with ML-KEM and ML-DSA, arXiv:2606.09412v1

This is not a 2040 problem you can defer. The confidentiality lifetime of the data you export this year already overlaps with credible quantum timelines. Every clinical export sealed with ECDH key exchange is a deposit into an attacker’s future-decryption account.

[IMAGE: A sealed steel vault of medical data records dissolving into quantum light streams, dark background with cyan accents]

Technical Deep-Dive: How the Pipeline Combines Four Primitives

The prototype does not invent new cryptography. It does something more useful for an enterprise architect: it shows exactly where each NIST-standardized primitive plugs into a real file-transfer workflow, and what role it plays.

The Cryptographic Stack, Layer by Layer

Definition — Hybrid PQC file transfer: a scheme that uses a post-quantum key-encapsulation mechanism (KEM) to establish a shared secret, derives a symmetric key from it, encrypts the payload with fast symmetric crypto, and signs the result with a post-quantum signature for integrity and authenticity.

The pipeline implements this as a four-stage chain:

1. Key establishment — ML-KEM-768. The lattice-based KEM (formerly Kyber, now FIPS 203) encapsulates a shared secret between sender and receiver. This is the layer that replaces quantum-vulnerable RSA/ECC key exchange.
2. Key derivation — HKDF-SHA-256. The KEM secret is run through HKDF to derive a clean AES key, rather than using raw KEM output directly.
3. Payload encryption — AES-256-GCM. Files are treated as raw bytes and encrypted with authenticated symmetric crypto. Metadata is preserved so the receiver can reconstruct the original file faithfully across formats.
4. Integrity and authenticity — ML-DSA-65. The lattice signature scheme (formerly Dilithium, now FIPS 204) signs the package, providing tamper detection and sender authentication that survives quantum attack.

The pipeline handles four file formats end to end — TXT, CSV, JSON, and PDF — by treating each as an opaque byte stream, which is why a single transport works for structured adverse-event tables and unstructured clinical PDFs alike.

The Most Important Performance Finding

The benchmarking component shows that ML-KEM contributes only a small constant overhead, while AES-256-GCM encryption and ML-DSA-65 signing increasingly dominate total runtime as file size grows.

That single result reorders your migration priorities. The instinct is to fear that post-quantum key exchange will throttle throughput. The data says the opposite: key establishment is effectively free at scale. Your real cost curve bends with payload size and signing — so capacity planning should target encryption throughput and signature batching, not KEM latency.

Classical vs. Post-Quantum Pipeline

Note what does not change: AES-256-GCM and HKDF-SHA-256 are retained as-is. Symmetric cryptography at 256-bit key length is already considered quantum-resistant, so the migration surgically replaces only the asymmetric layers. That is the practical reassurance most CISOs need — this is a targeted swap, not a ground-up rebuild.

Industry Context: A Reference Architecture, Not a Product

The prototype is built as six discrete components — hospital, gateway, pharma receiver, attacker, benchmarking, and dashboard — and that decomposition is the part enterprise architects should copy. It maps cleanly onto a real data-sharing topology: a data originator (hospital), a transport intermediary (gateway), a consumer (pharma receiver), an explicit adversary model (attacker), measurable performance (benchmarking), and observability (dashboard).

Crucially, the authors position this as an educational prototype that is explicitly not production-ready. That honesty matters. Treat it as a blueprint to validate your own migration assumptions — not as software to deploy. The value is in the wiring diagram and the benchmark insight, not in dropping the code into a regulated environment.

The regulatory tailwind is real. NIST finalized ML-KEM (FIPS 203) and ML-DSA (FIPS 204) as standards, and U.S. federal guidance has set the expectation that agencies and their suppliers inventory and migrate quantum-vulnerable cryptography this decade. For pharma and healthcare vendors selling into regulated buyers, demonstrating a credible PQC migration path is shifting from differentiator to procurement requirement. The cost of inaction is not just a future breach — it is being designed out of contracts that now ask for a cryptographic bill of materials.

The BeQuantum Perspective

We read this paper the way we read our own architecture reviews, because the four-layer pattern it validates is the same one underpinning BeQuantum’s PQC Layer and Digital Notary.

The paper’s headline performance result — that ML-DSA signing, not key exchange, dominates runtime at scale — is exactly why our Digital Notary treats signatures as the component to engineer around. When you are sealing thousands of clinical records or audit events, naive per-record ML-DSA-65 signing becomes the bottleneck the benchmarks predict. The mitigation is to anchor batches: sign a Merkle-aggregated commitment rather than every payload individually, then notarize that commitment so each record inherits tamper-evidence without paying a full signature each time. That is the practical translation of “signing dominates runtime” into an architecture that still scales.

For data at rest with decade-long confidentiality requirements, the pipeline’s retention of AES-256-GCM behind an ML-KEM-established key mirrors how we provision IceCase hardware-backed key custody: the symmetric layer stays, the asymmetric layer goes post-quantum, and the keys live in hardware so a harvested ciphertext is worthless without the device. Organizations like ours are not waiting for a vendor to hand us a finished product — we are porting exactly this validated primitive stack into instrumented, hardware-rooted deployments.

What You Should Do Next

1. Within 90 days — inventory your asymmetric crypto. Audit every TLS certificate chain, signing key, and key-exchange handshake touching data with a 5+ year confidentiality requirement. You cannot migrate what you have not catalogued; produce a cryptographic bill of materials first.
2. Within 6 months — pilot the hybrid pattern on one data flow. Pick your longest-lived export (clinical trial archives, adverse-event reports) and prototype ML-KEM-768 + HKDF-SHA-256 + AES-256-GCM + ML-DSA-65 in a test environment. Benchmark signing throughput specifically — that is where your production cost will concentrate.
3. Before your next procurement cycle — engineer for signing at scale. If your data volumes are high, design batch-signing or notarization aggregation now, rather than discovering the ML-DSA runtime cliff in production.

FAQ

Q: Do I need to replace AES encryption to be quantum-safe? A: No. AES-256-GCM at a 256-bit key length is already considered resistant to known quantum attacks, and the referenced pipeline retains it unchanged. The migration targets only the asymmetric layers — replacing RSA/ECC key exchange with ML-KEM and classical signatures with ML-DSA.

Q: Will post-quantum key exchange slow down my data pipeline? A: According to the benchmarks in arXiv:2606.09412v1, ML-KEM adds only a small constant overhead. The runtime cost that grows with file size comes from AES encryption and ML-DSA signing — so key establishment is not your scaling concern, signing is.

Q: Is this pipeline ready to deploy in a regulated healthcare environment? A: No. The authors explicitly describe it as an educational, non-production prototype evaluated on synthetic datasets. Use it as a reference architecture to validate your own migration design, not as deployable software.

Last updated: 2026-06-09. Source: Towards Post-Quantum Secure Pharmacovigilance with ML-KEM and ML-DSA, arXiv:2606.09412v1.